Sodium-glucose Linked Transporter 2 (SGLT-2) Inhibitors in Recurrent Ascites: a Pilot RCT
3. September 2021 aktualisiert von: Dr.Virendra Singh, Postgraduate Institute of Medical Education and Research
The development of ascites is a landmark event in the natural history of cirrhosis and signifies a grim prognosis. Portal hypertension and splanchnic arterial vasodilatation are the major contributors in the development of ascites. Vasodilatation with the consequential decrease in effective circulating volume leads to the activation of sympathetic nervous system and renin angiotensin aldosterone system (RAAS), leading to antinatriuretic effects and retention of sodium and water. This results in the formation of ascites. Management of ascites primarily consists of salt restrictrion and diuretics. Liver transplant is the ultimate panacea.
Dapaglifozin, a Sodium glucose linked transporter-2(SGLT-2) inhibitor, is a part of the routine armamentarium for treatment of patients with Diabetes Mellitus type-2. Its safety is well established in non-diabetic patients too where it has been shown to improve cardiovascular outcomes. The risk of hypoglycemia is negligible as its action is independent of insulin. By virtue of its natriuretic effect, it has been shown to reduce hospitalisations in patients with heart failure irrespective of the presence of diabetes. We hypothesise that a similar natriuretic effect may help in suppressing the renin-angiotensin axis with improved mobilization of ascites in patients with cirrhosis. Pharmacokinetic data on the use of Dapaglifozin suggest that there is no need for dose modification in cirrhosis. The AUC and Cmax for Dapaglifozin in Child Pugh C cirrhosis is 67% and 40%, respectively. In a recent small case series, SGLT-2 inhibitors including dapaglifozin led to improvement in fluid retention and serum sodium, without acute kidney injury or encephalopathy, in patients with cirrhosis. However, SGLT-2 inhibitors have not been evaluated in randomized controlled trials. In this pilot study, we plan to evaluate the efficacy and safety of dapaglifozin in cirrhotics patients with recurrent ascites.
Studienübersicht
Status
Rekrutierung
Bedingungen
Studientyp
Interventionell
Einschreibung (Voraussichtlich)
44
Phase
- Phase 2
Kontakte und Standorte
Dieser Abschnitt enthält die Kontaktdaten derjenigen, die die Studie durchführen, und Informationen darüber, wo diese Studie durchgeführt wird.
Studienkontakt
- Name: Virendra Singh, MD,DM,FASGE
- Telefonnummer: 0172-275-6338
- E-Mail: virendrasingh100@hotmail.com
Studieren Sie die Kontaktsicherung
- Name: Rishav Aggarwal, MBBS
- Telefonnummer: 9914032190
- E-Mail: rishavaggarwal90@gmail.com
Studienorte
-
-
-
Chandigarh, Indien, 160012
- Rekrutierung
- Dept of Hepatology, PGIMER
-
Kontakt:
- Virendra Singh, MD, DM
- Telefonnummer: +911722756338
- E-Mail: virendrasingh100@hotmail.com
-
-
Teilnahmekriterien
Forscher suchen nach Personen, die einer bestimmten Beschreibung entsprechen, die als Auswahlkriterien bezeichnet werden. Einige Beispiele für diese Kriterien sind der allgemeine Gesundheitszustand einer Person oder frühere Behandlungen.
Zulassungskriterien
Studienberechtigtes Alter
18 Jahre bis 70 Jahre (Erwachsene, Älterer Erwachsener)
Akzeptiert gesunde Freiwillige
Nein
Studienberechtigte Geschlechter
Alle
Beschreibung
Inclusion Criteria:
- Age 18-70 years
- Cirrhosis as determined by clinical findings, hemogram and liver function tests, endoscopic findings and imaging
- Recurrent ascites: Recurrent ascites will be defined as tense ascites recurring at least thrice within the last 1-year despite optimal standard medical treatment including large volume paracentesis and diuretics
Exclusion Criteria:
- Presence of chronic kidney disease as defined by an estimated glomerular filtration rate of <60 ml/min for more than 3 months. The MDRD-6 equation will be used for estimating GFR.
- Portal vein thrombosis
- Hepatocellular carcinoma.
- Gastrointestinal bleed in the preceding 2-weeks
- Overt hepatic encephalopathy in the preceding 1-month
- Documented hypoglycemia in the preceding 1-month
- Serum sodium < 125 meq/l
- History of skeletal fracture in the preceding year or any past history of fragility fracture
- History of peripheral vascular disease
- Acute kidney injury as defined by the International Club of Ascites criteria
- Infection within 1-month preceding the study
- Anatomic urologic defects that predispose to urinary tract infection
- Mixed ascites (additional etiology of ascites apart from portal hypertension)
- Any severe extra hepatic condition including respiratory and cardiac failure
- Acute-on-chronic liver failure as per the APASL or CANONIC criteria
- Treatment with drug with known effects on systemic and renal hemodynamics within 7 days of inclusion excepting beta-blockers
- Patients opting for liver transplant or TIPS
- Refusal to give consent
Studienplan
Dieser Abschnitt enthält Einzelheiten zum Studienplan, einschließlich des Studiendesigns und der Messung der Studieninhalte.
Wie ist die Studie aufgebaut?
Designdetails
- Hauptzweck: Behandlung
- Zuteilung: Zufällig
- Interventionsmodell: Parallele Zuordnung
- Maskierung: Vervierfachen
Waffen und Interventionen
Teilnehmergruppe / Arm |
Intervention / Behandlung |
|---|---|
|
Aktiver Komparator: Group A (Dapaglifozin)
Group A will receive oral Dapaglifozin (10 mg/day) along with standard medical therapy for 6 months
|
Oral Dapaglifozin (10 mg/day) along with standard medical therapy will be given to Group A while a placebo of dapaglifozin along with standard medical therapy will be used in Group B
|
|
Placebo-Komparator: Group B (Placebo)
Group B will receive placebo of Dapaglifozin along with standard medical therapy for 6 months
|
Standard medical therapy will include dietary restriction of sodium, treatment with diuretics, repeated LVP as needed and other supportive care.
Patients on non-selective beta blockers will continue to do so with dose modifications/withdrawal as per Baveno VI guidelines.
|
Was misst die Studie?
Primäre Ergebnismessungen
Ergebnis Maßnahme |
Maßnahmenbeschreibung |
Zeitfenster |
|---|---|---|
|
control of ascites at 6-months
Zeitfenster: 6 months
|
Control of ascites will be defined as follows-
|
6 months
|
Sekundäre Ergebnismessungen
Ergebnis Maßnahme |
Maßnahmenbeschreibung |
Zeitfenster |
|---|---|---|
|
Change in eGFR measured by MDRD-6 at 3 months and 6 months
Zeitfenster: 6 months
|
eGFR will be measured by MDRD-6 formula
|
6 months
|
|
Change in urine output at 2-weeks, 3-months and 6-months
Zeitfenster: 6-months
|
Change in 24-hour urine output (ml) at 6-months
|
6-months
|
|
Change in serum sodium (mEq/l) at 2-weeks, 3-months and 6 months
Zeitfenster: 6 months
|
Change in serum sodium (mEq/l)
|
6 months
|
|
Change in 24-hours urinary sodium (mEq) at 2 weeks, 3 months and 6 months
Zeitfenster: 6 months
|
Change in 24-hours urinary sodium (mEq)
|
6 months
|
|
Change in HbA1c at 3 and 6 months
Zeitfenster: 6 months
|
Change in HbA1c
|
6 months
|
|
Change in Child-Turcotte-Pugh (CTP) score at 3 months and 6 months
Zeitfenster: 6 months
|
Change in CTP score.
The CTP score incorporates the variables of serum bilirubin, albumin, prothrombin time-INR, grade of ascites and hepatic encephalopathy.
The score ranges from 5-15 and a higher score portends a worse prognosis
|
6 months
|
|
Change in model for end stage liver disease (MELD) score at 3 months and 6 months
Zeitfenster: 6 months
|
Change in MELD score.
The MELD score incorporates the variables of serum bilirubin, creatinine and Internation Normalised Ratio (INR).
Higher MELD score indicates worse prognosis
|
6 months
|
|
Incidence of spontaneous bacterial peritonitis (SBP), urinary tract infection (UTI) and other infections
Zeitfenster: 6 months
|
The diagnosis of SBP will be based on neutrophil count in ascitic fluid of >250/mm3 as determined by microscopy and positive ascitic fluid culture or >250 /mm3 with negative culture called as culture negative neutrocytic ascites.Other infections will be diagnosed as per CDC criteria.
|
6 months
|
|
Incidence of overt hepatic encephalopathy over 6-months
Zeitfenster: 6 months
|
Over hepatic encephalopathy (HE) will be defined as grade II or higher HE as per the West haven classification
|
6 months
|
|
Incidence of acute kidney injury over 6-months
Zeitfenster: 6 months
|
Acute kidney injury will be defined as per the International Club of Ascites criteria
|
6 months
|
|
Incidence of Hyponatremia (serum sodium <130 meq/L), hypokalemia (Serum potassium < 3.5 meq/L), hyperkalemia (Serum potassium >6meq/L) over 6-months.
Zeitfenster: 6 months
|
Hyponatremia: serum sodium <130 meq/L hypokalemia: serum potassium < 3.5 meq/L hyperkalemia: serum potassium >6meq/L)
|
6 months
|
|
Incidence of skeletal fractures over 6-months
Zeitfenster: 6 months
|
Incidence of skeletal fractures over 6-months
|
6 months
|
|
Change in bone densitometry as assessed by DEXA at 6-months
Zeitfenster: 6 months
|
Bone densitometry will be assessed by DEXA
|
6 months
|
|
Incidence of diabetic ketoacidosis or hyperglycemic hyperosmolar nonketotic coma over 6-months
Zeitfenster: 6 months
|
Incidence of diabetic ketoacidosis or hyperglycemic hyperosmolar nonketotic coma over 6-months
|
6 months
|
|
Incidence of hepatocellular carcinoma over 6-months
Zeitfenster: 6 months
|
Hepatocellular carcinoma will be diagnosed based on imaging findings and AFP
|
6 months
|
|
Changes in plasma renin activity and aldosterone levels at 6- months
Zeitfenster: 6 months
|
Changes in plasma renin activity (ng/ml/hr) and aldosterone (ng/dL) levels at 6- months
|
6 months
|
|
Frequency and volume of LVP over 6-months.
Zeitfenster: 6 months
|
Frequency and volume of ascitic fluid removed (in litres) over 6-months.
|
6 months
|
|
Survival at 6-months
Zeitfenster: Survival at 6-months
|
Survival at 6-months after start of therapy
|
Survival at 6-months
|
|
Safety of dapaglifozin as assessed by adverse effects
Zeitfenster: 6 months
|
Safety of dapaglifozin as assessed by adverse effects
|
6 months
|
|
Renal resistive index at 6 months
Zeitfenster: 6 months
|
Renal resistive index will be measured using ultrasound doppler interrogation of intrarenal arteries using formula (peak systolic velocity - end-diastolic velocity) / peak systolic velocity
|
6 months
|
Mitarbeiter und Ermittler
Hier finden Sie Personen und Organisationen, die an dieser Studie beteiligt sind.
Studienaufzeichnungsdaten
Diese Daten verfolgen den Fortschritt der Übermittlung von Studienaufzeichnungen und zusammenfassenden Ergebnissen an ClinicalTrials.gov. Studienaufzeichnungen und gemeldete Ergebnisse werden von der National Library of Medicine (NLM) überprüft, um sicherzustellen, dass sie bestimmten Qualitätskontrollstandards entsprechen, bevor sie auf der öffentlichen Website veröffentlicht werden.
Haupttermine studieren
Studienbeginn (Tatsächlich)
3. September 2021
Primärer Abschluss (Voraussichtlich)
19. Mai 2022
Studienabschluss (Voraussichtlich)
19. Mai 2022
Studienanmeldedaten
Zuerst eingereicht
14. August 2021
Zuerst eingereicht, das die QC-Kriterien erfüllt hat
14. August 2021
Zuerst gepostet (Tatsächlich)
20. August 2021
Studienaufzeichnungsaktualisierungen
Letztes Update gepostet (Tatsächlich)
5. September 2021
Letztes eingereichtes Update, das die QC-Kriterien erfüllt
3. September 2021
Zuletzt verifiziert
1. September 2021
Mehr Informationen
Begriffe im Zusammenhang mit dieser Studie
Zusätzliche relevante MeSH-Bedingungen
Andere Studien-ID-Nummern
- Dapa recurrent ascites
Arzneimittel- und Geräteinformationen, Studienunterlagen
Studiert ein von der US-amerikanischen FDA reguliertes Arzneimittelprodukt
Nein
Studiert ein von der US-amerikanischen FDA reguliertes Geräteprodukt
Nein
Diese Informationen wurden ohne Änderungen direkt von der Website clinicaltrials.gov abgerufen. Wenn Sie Ihre Studiendaten ändern, entfernen oder aktualisieren möchten, wenden Sie sich bitte an register@clinicaltrials.gov. Sobald eine Änderung auf clinicaltrials.gov implementiert wird, wird diese automatisch auch auf unserer Website aktualisiert .